By Dan Stanton
Data must drive US FDA efforts to determine biosimilar interchangeability according to a Pfizer exec who told Goldman Sachs conference delegates not to expect a definition anytime soon.
Read more at http://www.biopharma-reporter.com/Markets-Regulations/Pfizer-No-biosimilar-interchangeability-in-near-future
